|
1
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3(75ra26)2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Minari R, Bordi P, Del Re M, Facchinetti
F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C,
et al: Primary resistance to osimertinib due to SCLC
transformation: Issue of T790M determination on liquid re-biopsy.
Lung Cancer. 115:21–27. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Iijima Y, Hirotsu Y, Mochizuki H, Amemiya
K, Oyama T, Uchida Y, Kobayashi Y, Tsutsui T, Kakizaki Y, Miyashita
Y and Omata M: Dynamic changes and drug-induced selection of
resistant clones in a patient with EGFR-mutated adenocarcinoma that
acquired T790M mutation and transformed to small-cell lung cancer.
Clin Lung Cancer. 19:e843–e847. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Taniguchi Y, Horiuchi H, Morikawa T and
Usui K: Small-cell carcinoma transformation of pulmonary
adenocarcinoma after osimertinib treatment: A case report. Case Rep
Oncol. 11:323–329. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kim TM, Song A, Kim DW, Kim S, Ahn YO,
Keam B, Jeon YK, Lee SH, Chung DH and Heo DS: Mechanisms of
acquired resistance to AZD9291: A mutation-selective, irreversible
EGFR inhibitor. J Thorac Oncol. 10:1736–1744. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ham JS, Kim S, Kim HK, Byeon S, Sun JM,
Lee SH, Ahn JS, Park K, Choi YL, Han J, et al: Two cases of small
cell lung cancer transformation from EGFR mutant adenocarcinoma
during AZD9291 treatment. J Thorac Oncol. 11:e1–e4. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Marcoux N, Gettinger SN, O'Kane G, Arbour
KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi
PD, et al: EGFR-mutant adenocarcinomas that transform to small-cell
lung cancer and other neuroendocrine carcinomas: Clinical outcomes.
J Clin Oncol. 37:278–285. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Oser MG, Niederst MJ, Sequist LV and
Engelman JA: Transformation from non-small-cell lung cancer to
small-cell lung cancer: Molecular drivers and cells of origin.
Lancet Oncol. 16:e165–e172. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hayano M, Hokamura Y, Kimura Y, Kimura T
and Tokube K: Clinical studies of 16 cases of carcinomatous
pericarditis. Kokyu To Junkan. 39:683–686. 1991.PubMed/NCBI(In Japanese).
|
|
13
|
Wang PC, Yang KY, Chao JY, Liu JM, Perng
RP and Yen SH: Prognostic role of pericardial fluid cytology in
cardiac tamponade associated with non-small cell lung cancer.
Chest. 118:744–749. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kato R, Hayashi H, Chiba Y, Tanaka K,
Takeda M and Nakagawa K: Prognostic impact of minimal pericardial
effusion in patients with advanced non-small-cell lung cancer. Clin
Lung Cancer. 18:e449–e455. 2017.PubMed/NCBI View Article : Google Scholar
|
